Kyowa Hakko Kogyo Co., Ltd.

Fancl Corporation

Nippon Beet Sugar Manufacturing., Co., Ltd.

Ajinomoto Co., Ltd.

Kyowa Hakko Kogyo Kabushiki Kaisha

Nippon Beet Sugar Mfg., Co., Ltd.

Fusao Tomita

Hirofumi Nakano

Makoto Morimoto

Kunikatsu Shirahata

Tatsuya Tamaoki

Keiichi Takahashi

Tsutomu Aritsuka

Hiroto Kikuchi

Kozo Asano

Isao Kawamoto

Isami Takahashi

Atsushi Yokota

Kazuhisa Fujimoto

Akiko Tamura

Norihiro Shigematsu

Takuya Shiomi

Shuji Okubo

Nobuo Nakamura

Yasuhide Okuhara

Kyoko Tomita

Masaji Kasai

Osamu Kurahashi

Tadashi Ashizawa

Toru Yasuzawa

Kenichi Hashiguchi

Tomoyasu Sato

Masako Ishigooka

Hiroshi Sano

Yuzuru Matsuda

Tetsuo Oka

Takao Iida

Noriaki Hirayama

Kenjiro Shimada

Norimitsu Takagi

Michio Ichimura

Hisayo Nomoto

Kozo Asasno

Hiroaki Sakurai

Yuzura Matsuda

Masanori Fukui

Yoshihiro Senba

Shingo Ito

Masao Otomo

Akiko c/o Central Research Center Tamura

Takuya c/o Central Research Center Shiomi

Kyoko c/o Central Research Center Tomita

Norihiro c/o Central Research Center Shigematsu

A method for increasing the absorption of magnesium, zinc, and/or copper through the intestines of a subject desiring such an increase, includes administering to the subject a difructose anhydride (DFA) in an amount effective to increase the absorption of magnesium, zinc, and/or copper present in the intestines.

Use of difructose anhydride-containing composition

In the invention, highly pure crystals of difructose dianhydride III (di-D-fructofuranose-1,2':2,3&#x2032;-dianhydride; hereinafter referred to as DFA III) are produced by adding 5% or less of powdered active carbon to a DFA III containing purified solution containing DFA III of 90% or more purity at a concentration of R-Bx 10-60, preferably 40-55, and after stirring, applying the mixture to solid-liquid separation (filtration with diatomaceous, filtration through a membrane filter, ultrafiltration, or continuous centrifugal separation) and concentrating the separated liquid part, followed by immediate crystallization. In the process of the invention, DFA III crystals can be produced efficiently and industrially, and the resulting crystals can be used for various purposes in pharmaceuticals or food and drink since they have no smell. This is characteristics of the invention different from the prior art products.

Process for purifying difructose dianhydride III

A method for improving bowel movement of a subject desiring such an improvement, includes administering to the subject a defructose anhydride (DFA) in an amount effective to improve bowel movement.

The present invention relates to a difructose anhydride (DFA)-containing composition and use thereof. DFA is a cyclic disaccharide in which the reducing termini of two fructose molecules bind each other to hydroxyl groups at the other nonreducing termini. According to the present invention, it has been revealed that DFA is effective in accelerating the absorption of magnesium, zinc or copper, accelerating bone formation, accelerating diuretic action, and improving bowel movement and is useful in inhibiting dental caries. A composition of the present invention can be used as a composition for a medicinal product and a food or drink product (including feed for animal use). Examples of a medicinal product and a food or drink product for human or animal use include formulated powder milk, parenteral nutrients, health food and drink products, and additives for feed and are not particularly limited as long as they are ultimately in an orally administrable form.

Difructose anhydride-containing composition and use thereof

Provided are a protein complex having the FF-ATPase activity; a DNA encoding the protein complex; a method for producing the protein complex, using the DNA; and a method for producing nucleoside 5'-triphosphate using the protein. The present invention further provides a recombinant DNA with the DNA inserted therein; a transformant carrying the recombinant DNA; and a method for producing a protein complex, using the transformant.

[object Object]

L-valine is produced by culturing a microorganism belonging to the genus Escherichia with the capability of producing L-valine or L-leucine wherein it requires lipoic acid for growth, a microorganism belonging to the genus Escherichia with the capability of producing L-valine or L-leucine wherein it is deficient in H,-ATPase activity, a microorganism belonging to the genus Escherichia wit the capability of producing L-valine or L-leucine wherein it requires lipoic acid for growth and is deficient in H,-ATPase activity, in the liquid medium to allow the L-valine to be produced and accumulated in a culture medium, and collecting it.

Methods for producing L-valine and L-leucine

UCN-01 having an anti-tumor activity and an anti-bacterial activity is produced by culturing a microorganism belonging to the genus Streptomyces.

UCN-01 and process for production thereof

The present invention relates to DC-88A and DC-89A1 and their production. These compounds are obtained by fermentation of microorganisms belonging to the genus Streptomyces. These compounds have antibacterial and anti-tumor activities and are useful as medicaments.

Pyrindamycins A and B and duocarmycin A antibiotics derived from certain

Antibiotic compounds DC-92B and DC-92D

Phenazine compounds represented by the formula: ##STR1## wherein R is a hydrogen atom, an unsubstituted or substituted lower alkanoyl group, or an unsubstituted or substituted arylcarbonyl group have antibacterial and anti-tumor activities. Some of these compounds are produced by incubation of a microorganism.

Phenazine carboxylic acid derivatives and a process for production

Tetrocarcins have remarkable and anti-piroplasma activity and anti-malaria activity, and especially useful for preventing or curing piroplasma disease of cattle.

Pharmaceutical composition for treating protozoan disease containing at

New substances designated as DC-45-A, DC-45-B.sub.1 and DC-45-B.sub.2 and represented by the following general formula: ##STR1## wherein (i) R.sub.1 and R.sub.2 together with the carbon atom therebetween represent the group ##STR2## and R.sub.3 represents ##STR3## (designated DC-45-A); (ii) R.sub.1 represents --OH, R.sub.2 represents --CH.sub.2 OH and R.sub.3 represents ##STR4## (designated DC-45-B.sub.1); or (iii) R.sub.1 and R.sub.2 together with the carbon atom therebetween represent the group ##STR5## and R.sub.3 represents ##STR6## (designated DC-45-B.sub.2). DC-45-A, DC-45-B.sub.1 and DC-45-B.sub.2 possess antibiotic and anti-tumor activity and may be obtained by culturing a microorganism of the genus Streptomyces. Preferred strain is Streptomyces bottropensis (FERM-P No. 5219; NRRL 12051).

Antibiotic substances DC-45, and their use as medicaments

The antibacterial compound DC-38-V is produced by culturing a microorganism belonging to the genus Streptomyces.

Compound DC-38-V and process for production thereof

New antibacterial tetronolide compounds F-1 and F-2 are produced by fermentation of a microorganism belonging to the genus Micromonospora. The antibiotics F-1 and F-2 are accumulated in the culture liquor and are isolated therefrom respectively and the acyl derivatives of F-1 and F-2, that is, F-1-21-O-acetate, F-1-21-O-propionate, F-1-21-O-n-butylate, F-1 diacetate, F-1 dipropionate, F-2 triacetate, F-2 tripropionate and F-2 tri-n-butylate, etc., are synthesized from F-1 and F-2 by known means.

Antibiotics tetronolide compounds and process for production thereof

Growing community of inventors

Sapporo, Japan

Fusao Tomita